These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 28483373

  • 1. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M, García-Garzón JR, Moragas-Freixa M, Soler-Peter M, Bassa Massanas P, Sánchez-Delgado M, Sanchez-Jurado R, Aguilar-Barrios JE, Sanz-Llorens R, Ferrer-Rebolleda J.
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma.
    Duarte S, Roque A, Saraiva T, Afonso C, Marques BA, Lima CB, Neves D, Lai AC, Costa G, Cipriano A, Geraldes C, Ruzickova L, Carda JP, Gomes M.
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [Abstract] [Full Text] [Related]

  • 4. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method.
    Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, Franzius C, Weckesser M, Bengel FM, Freesmeyer M, Hertel A, Krohn T, Holzinger J, Brink I, Haberkorn U, Nyuyki F, van Assema DME, Geworski L, Hasenclever D, Jöckel KH, Dührsen U.
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
    Santos FM, Marin JFG, Lima MS, Silva-Junior WF, Alves LBO, Moreira FR, Velasques RD, Atanazio MJ, Maia ACA, Buchpiguel CA, Buccheri V, Rocha V.
    Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment 18F-FDG PET in Diffuse Large B-Cell Lymphoma.
    Györke T, Carr R, Cerci JJ, Meneghetti C, Redondo F, Celli M, Gorospe C, Auewarakul CU, Jorgov L, Paez D, Fanti S.
    J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
    Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Véra P, Tilly H, Siegel BA, Gallamini A, Casasnovas RO, Haioun C.
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
    de Oliveira Costa R, Hallack Neto A, Siqueira S, Lage LA, de Paula HM, Coutinho AM, Pereira J.
    Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
    [Abstract] [Full Text] [Related]

  • 15. [Values of Different Evaluation Criteria of Interim 18F-FDG PET/CT Scan for Prediction of Prognosis in Patients with DLBCL].
    Zhu LT, Cen XN, Ou JP, Qiu ZX, Wang LH, Liu W, Wang WS, Dong YJ, Liang ZY, Wang MJ, Xu WL, Sun YH, Wang Q, Yin Y, Ren HY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [Abstract] [Full Text] [Related]

  • 16. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
    Xie W, Liu MK, Jiang XF, Gao XD, Li B, Wang L, Zhao WL.
    Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
    [Abstract] [Full Text] [Related]

  • 17. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?
    Le Gouill S, Casasnovas RO.
    Blood; 2017 Jun 08; 129(23):3059-3070. PubMed ID: 28416502
    [Abstract] [Full Text] [Related]

  • 18. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
    Biggi A, Bergesio F, Chauvie S, Bianchi A, Menga M, Fallanca F, Hutchings M, Gregianin M, Meignan M, Gallamini A.
    Q J Nucl Med Mol Imaging; 2021 Dec 08; 65(4):410-415. PubMed ID: 28750493
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
    Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM, HOVON Imaging Working Group and the HOVON Lymphoma Working Group.
    J Nucl Med; 2022 Jul 08; 63(7):1001-1007. PubMed ID: 34675112
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.